161 related articles for article (PubMed ID: 18979199)
21. Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype.
Ito Y; Kawakatsu H; Takeda T; Sakon M; Nagano H; Sakai T; Miyoshi E; Noda K; Tsujimoto M; Wakasa K; Monden M; Matsuura N
J Hepatol; 2001 Jul; 35(1):68-73. PubMed ID: 11495044
[TBL] [Abstract][Full Text] [Related]
22. Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma.
Itoh S; Maeda T; Shimada M; Aishima S; Shirabe K; Tanaka S; Maehara Y
Clin Cancer Res; 2004 Apr; 10(8):2812-7. PubMed ID: 15102689
[TBL] [Abstract][Full Text] [Related]
23. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation.
Sun CK; Man K; Ng KT; Ho JW; Lim ZX; Cheng Q; Lo CM; Poon RT; Fan ST
Carcinogenesis; 2008 Nov; 29(11):2096-105. PubMed ID: 18765415
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
Schweppe RE; Kerege AA; French JD; Sharma V; Grzywa RL; Haugen BR
J Clin Endocrinol Metab; 2009 Jun; 94(6):2199-203. PubMed ID: 19293266
[TBL] [Abstract][Full Text] [Related]
25. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
Nakai S; Masaki T; Shiratori Y; Ohgi T; Morishita A; Kurokohchi K; Watanabe S; Kuriyama S
Int J Oncol; 2002 Apr; 20(4):769-75. PubMed ID: 11894123
[TBL] [Abstract][Full Text] [Related]
26. Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma.
Masaki T; Okada M; Tokuda M; Shiratori Y; Hatase O; Shirai M; Nishioka M; Omata M
Hepatology; 1999 Feb; 29(2):379-84. PubMed ID: 9918913
[TBL] [Abstract][Full Text] [Related]
27. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Eustace AJ; Crown J; Clynes M; O'Donovan N
J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
[TBL] [Abstract][Full Text] [Related]
28. FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma.
Shang N; Arteaga M; Zaidi A; Cotler SJ; Breslin P; Ding X; Kuo P; Nishimura M; Zhang J; Qiu W
Gene Expr; 2016; 17(1):79-88. PubMed ID: 27142958
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection.
Hu TH; Wang CC; Huang CC; Chen CL; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Tai MH
Oncol Rep; 2007 Dec; 18(6):1417-26. PubMed ID: 17982625
[TBL] [Abstract][Full Text] [Related]
30. In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Chang AY; Wang M
Anticancer Drugs; 2013 Mar; 24(3):251-9. PubMed ID: 23187461
[TBL] [Abstract][Full Text] [Related]
31. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.
Niwa Y; Kanda H; Shikauchi Y; Saiura A; Matsubara K; Kitagawa T; Yamamoto J; Kubo T; Yoshikawa H
Oncogene; 2005 Sep; 24(42):6406-17. PubMed ID: 16007195
[TBL] [Abstract][Full Text] [Related]
32. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
Golubovskaya VM; Virnig C; Cance WG
Mol Carcinog; 2008 Mar; 47(3):222-34. PubMed ID: 17849451
[TBL] [Abstract][Full Text] [Related]
33. Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways.
Acosta JJ; Muñoz RM; González L; Subtil-Rodríguez A; Dominguez-Caceres MA; García-Martínez JM; Calcabrini A; Lazaro-Trueba I; Martín-Pérez J
Mol Endocrinol; 2003 Nov; 17(11):2268-82. PubMed ID: 12907754
[TBL] [Abstract][Full Text] [Related]
34. Proliferating cell nuclear antigen (PCNA) activity in hepatocellular carcinoma, benign peri-neoplastic and normal liver.
Mun KS; Cheah PL; Baharudin NB; Looi LM
Malays J Pathol; 2006 Dec; 28(2):73-7. PubMed ID: 18376794
[TBL] [Abstract][Full Text] [Related]
35. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
36. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
[TBL] [Abstract][Full Text] [Related]
37. FAK is involved in invasion and metastasis of hepatocellular carcinoma.
Chen JS; Huang XH; Wang Q; Chen XL; Fu XH; Tan HX; Zhang LJ; Li W; Bi J
Clin Exp Metastasis; 2010 Feb; 27(2):71-82. PubMed ID: 20180147
[TBL] [Abstract][Full Text] [Related]
38. Cellular apoptosis susceptibility protein and proliferation in human hepatocellular carcinoma.
Shiraki K; Fujikawa K; Sugimoto K; Ito T; Yamanaka T; Suzuki M; Yoneda K; Sugimoto K; Takase K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):77-81. PubMed ID: 16786158
[TBL] [Abstract][Full Text] [Related]
39. [Expression of proliferating cell nucleus antigen and nm23 protein and their relation with metastasis in hepatocellular carcinoma].
Luo HY; Wang HC; Feng DY
Hunan Yi Ke Da Xue Xue Bao; 2003 Feb; 28(1):17-9. PubMed ID: 12934386
[TBL] [Abstract][Full Text] [Related]
40. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
